These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 14983962)

  • 1. Four-year prostate-specific antigen progression in the non-cancer population of the European Randomized Study of Screening for Prostate Cancer.
    Páez A; Luján M; Raaijmakers R; Berenguer A;
    BJU Int; 2003 Dec; 92 Suppl 2():84-7. PubMed ID: 14983962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
    Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
    J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
    Candas B; Labrie F; Gomez JL; Cusan L; Chevrette E; Lévesque J; Brousseau G
    J Urol; 2006 Feb; 175(2):510-6; discussion 516-7. PubMed ID: 16406983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
    Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
    JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less.
    Ito K; Yamamoto T; Suzuki K; Kurokawa K; Yamanaka H
    J Urol; 2004 Feb; 171(2 Pt 1):656-60. PubMed ID: 14713780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Int J Cancer; 2004 Apr; 109(3):455-60. PubMed ID: 14961587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: the clinician's dilemma.
    Kehinde EO; Sheikh M; Mojimoniyi OA; Francis I; Anim JT; Nkansa-Dwamena D; Al-Awadi KA
    BJU Int; 2003 May; 91(7):618-22. PubMed ID: 12699471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
    D'Amico AV; Renshaw AA; Sussman B; Chen MH
    JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.
    Kundu SD; Grubb RL; Roehl KA; Antenor JA; Han M; Catalona WJ
    J Urol; 2005 Apr; 173(4):1116-20. PubMed ID: 15758718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
    J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network.
    Finne P; Finne R; Auvinen A; Juusela H; Aro J; Määttänen L; Hakama M; Rannikko S; Tammela TL; Stenman U
    Urology; 2000 Sep; 56(3):418-22. PubMed ID: 10962306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less.
    Harris CH; Dalkin BL; Martin E; Marx PC; Ahmann FR
    J Urol; 1997 May; 157(5):1740-3. PubMed ID: 9112517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
    Aus G; Damber JE; Khatami A; Lilja H; Stranne J; Hugosson J
    Arch Intern Med; 2005 Sep; 165(16):1857-61. PubMed ID: 16157829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
    Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
    Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.